{"preliminary_commentary":{"by_channel":{"x_thread":36,"youtube":11,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07011719\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T06:12:15.661Z","note":"Automated from the 36 newest of 49 indexed sources (Oct 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":36,"text":"- Whether adding casdatifan improves outcomes beyond cabozantinib\n- How anemia and hypoxia may affect tolerability of casdatifan plus cabozantinib\n- How PEAK-1 may shape treatment sequencing after immunotherapy\n\nAlso discussed: other HIF-2α inhibitor combinations."},"drugs_tested":[["casdatifan","cabozantinib"]],"indication":"advanced clear cell renal cell carcinoma","name":"PEAK-1","nct_id":"NCT07011719","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=peak-1-nct07011719. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Casdatifan and cabozantinib taken orally","label":"Arm A (Experimental Arm)","type":"EXPERIMENTAL"},{"description":"Placebo and cabozantinib taken orally","label":"Arm B (Comparator Arm)","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Metastatic Clear Cell Renal Cell Carcinoma","Advanced Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":720,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Casdatifan","otherNames":["AB521"],"type":"DRUG"},{"name":"Cabozantinib","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1","timeFrame":"up to approximately 33 months"}],"references":[{"citation":"Mailyan AK, Mata G, Beatty JW, Drew SL, Fournier J, Yu K, Gal B, Kalisiak J, Yan X, Tran A, Su Y, Rosen BR, Jeffrey JL, Hardman C, Epplin M, Ginn E, Sun M, Chen A, Fabila P, Sivick KE, Schweickert PG, Piovesan D, Meleza C, Pham AT, Chen PY, Jin L, Walters MJ, Walker NP, Kwon HJ, Leleti MR, Powers JP, Lawson KV. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2alpha. J Med Chem. 2026 Jun 25;69(12):14952-14988. doi: 10.1021/acs.jmedchem.5c03724. Epub 2026 Jun 5.","pmid":"42246926","type":"DERIVED"}],"start_date":{"date":"2025-09-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT07011719"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/peak-1-nct07011719"}